Ono Pharmaceutical, Banyu Pharmaceutical Jointly Confirm Hypoglycemic Effect of DPP4 Inhibitor Sitagliptin.Tokyo, Japan, June 15, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Ono Pharmaceutical and Banyu Pharmaceutical have obtained positive results in the recent clinical trials of sitagliptin, a dipeptidyl peptidase IV (DPP4) inhibitor. In the trials, the two companies verified that sitagliptin exerts a hypoglycemic hypoglycemic /hy·po·gly·ce·mic/ (-gli-sem´ik) 1. pertaining to, characterized by, or causing hypoglycemia. 2. an agent that lowers blood glucose levels. effect equivalent to glipizide (sulfonylurea sulfonylurea /sul·fo·nyl·urea/ (sul?fo-nil-u-re´ah) any of a class of compounds that exert hypoglycemic activity by stimulating the islet tissue to secrete insulin; used to control hyperglycemia in patients with type 2 diabetes mellitus ). Further, the subjects administered with sitagliptin have substantially lost their weight compared to those with glipizide. Sitagliptin, which is currently developed by US pharmaceutical firm Merck, is an oral DPP-4 inhibitor with a hypoglycemic mechanism different from the conventional agents. It can exert beneficial effects with once-a-day dosage. Details of the results were presented at the 66th Scientific Sessions of American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of . Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion